Department：HPB Surgery
Medical School：Zhejiang University School of Medicine, China
Academic Rank：Associate Professor
Oncology pharmacology
Drug toxicology
Excellent Achievement Award of Ministry of Education, Second Prize, 2017
Zhejiang Natural Science Award of, Third Prize, 2016
High level of 151 Talent Projects of Zhejiang Province, 2014
Zhejiang Natural Science Award, Second Prize, 2014
Excellent Achievement Award of Ministry of Education, Second Prize, 2014
Natural Science Award of China Medical Society, Second Prize, 2014
President, Zhejiang Provincial Key Laboratory for Preclinical research of anticancer drugs
Standing Member, Committee of Toxicology Substitution and Translational Toxicology, Chinese society of toxicology
Member, Anti-Cancer Drug Committee, China Anti-Cancer Association
Standing Member, Zhejiang Pharmaceutical Association
Chair, Drug Toxicology Committee, Zhejiang Pharmaceutical Association
Vice Chair, Zhejiang Pharmacology Society
The team of Dr. He aims to identify and verify the potential novel drug targets based on the molecular understanding of the process of the chronic non-communicate diseases, especially for cancer.
They are particularly interested in the enzymes and transcriptional factors involving in the diseases initiation and progression. So far, they has led to identification of a series of key regulators including WSB1, DJ-1, YAP and IGF-1R, which might be served as the potential drug targets for controlling cancer malignant progression.
Now, they are further developing small molecule inhibitors to target these enzymes or transcriptional factors and investigate their potentials in treating human diseases, such as cancer.
Zhou Q#, Xian M#, Xiang SF, Xiang D, Shao X, Wang J, Cao J, Yang X, Yang B, Ying M*, He Q*. All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. Cancer Immunology Research. 2017 Jul;5(7):547-559.
Ying MD, Shao XJ, Jing H, Liu YJ, Qi XT, Cao J, Chen YQ, Xiang SF, Song H, Hu RG, Wei GQ, Yang B*, He QJ*.Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood. 2018 Jun 14;131(24):2698-2711.
Luo PH*, Xu ZF, Li GQ, Yan H, Zhu Y, Zhu H, Ma SL, Yang B*, He QJ*. HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy. 2018; 14(12): 2155-2170.
Zhu H, Wang DD, Yuan T, Yan FJ, Zeng CM, Dai XY, Chen ZB, Chen Y, Zhou TY, Fan GH, Ying MD, Cao J, Luo PH, Liu XJ, Hu YD, Peng Y, He QJ*, Yang B*. Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis. Cancer Research. 2018 Jul 15;78(14):3995-4006.
Zhu H#, Chang L#, Yan F, Hu Y, Zeng C, Zhou T, Yuan T, Ying M, Cao J, He Q* , Yang B*.AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. Theranostics. 2018; 8(3): 676-692.
Ding L, Chen X, Xu X, Qian Y, Liang G, Yao F, Yao Z, Wu H, Zhang J, He Q*, Yang B*.PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunology Research. 2019 Jan;7(1):136-149.
Zhu H#, Hu Y#, Zeng CM#, Chang LL, Ge FJ, Wang WH, Yan FJ, Zhao QX, Cao J, Ying MD, Gu YC, Zheng L, He QJ*, Yang B*. The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer. Theranostics. 2020 Jan 12; 10(5): 2188-2200.
Zhu H#, Yan FJ#, Yuan T, Qian MJ, Zhou TY, Dai XY, Cao J, Ying MD, Dong XW, He QJ*, Yang B*. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ. Cancer Research. 2020; 80(11):2204-2216.
Weng Q, Zhao M, Zheng J, Yang L, Xu Z, Zhang Z, Wang J, Wang J, Yang B, Richard Lu Q, Ying M*, He Q*. STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia. Cell Death and Differentiation. 2020 Jan; 27(1): 130-145.
Luo PH, Yan H, Chen XQ, Zhang Y, Zhao ZY, Cao J, Zhu Y, Du JX, Xu ZF, Zhang XC, Zeng S, Yang B*, Ma SL*, He QJ*. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes contributes to sorafenib-induced hand-foot skin reaction. Cell Research. 2020 Apr 15. doi: 10.1038/s41422-020-0309-6.
The mechanismresearch of MAT1 active cleavage fragment pM9 for myeloid leukemia therapy. Funding Source: National Natural Science Foundation of China.
The research of differentiation ofleukemia cell through a cell cycle independent mechanism by ubiquitin proteasome-dependent degradation of CDK2. Funding Source: National Natural Science Foundation of China.
The role of hypoxia in the promotion of tumor malignant transformation by uncontrollable inflammation. Funding Source: Major Projects of Natural Science Foundation of China.
Preclinical evaluation technology platform for new drugs against malignant tumor, cardiac and cerebral vascular disease and nervous system disease. Funding Source: The Construction of National Major Drug Creation&Innovative Drug Research and Development Technology Platform.
Preclinical study of hypoxia selective anti-tumor candidate compounds Q39(Western Medicine type1). Funding Source: National Major Drug Creation & Innovative Drug Research.
The mechanism research of proteasome inhibitors with retinoic acid drugs inducing tumor cell differentiation. Funding Source: National Natural Science Foundation of China.
The effect of CAK phosphorylation on ubiquitin proteasome. Funding Source: National Natural Science Foundation of China.
88 Jiefang Road,Shangcheng District Hangzhou,China, 310009
1511 Jianghong Road,Binjiang District Hangzhou,China, 310014
300 Yuanju Road, Shangcheng DIstrict, Hangzhou
456 Qidi Road, Xiaoshan District, Hangzhou, China
1 Xihu Avenue, Shangcheng District, Hangzhou
Zijingang Campus of Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou
Please call +86-571-8971 3988 (8am-5pm, Monday through Friday)
Make an appointment online
The Second Affiliated Hospital
Zhejiang University School of Medicine
88 Jiefang Road, Hangzhou, China
+86-571-8731 5108
iao_sahzu@zju.edu.cn
The Needs of Patients and Customers Come First.
The Second Affiliated Hospital Zhejiang University School of Medicine
All Rights Reserved.
